BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/3/2021 7:34:23 AM | Browse: 305 | Download: 352
 |
Received |
|
2021-07-04 00:39 |
|
Peer-Review Started |
|
2021-07-04 00:45 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-08-08 03:37 |
|
Revised |
|
2021-08-11 18:31 |
|
Second Decision |
|
2021-11-23 03:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-11-25 01:26 |
|
Articles in Press |
|
2021-11-25 01:26 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-11-30 23:43 |
|
Publish the Manuscript Online |
|
2021-12-03 07:34 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Therapeutic potentials of fasudil in liver fibrosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yue Xi and Peng-Fei Xu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peng-Fei Xu, PhD, Academic Research, Postdoctoral Fellow, Research Associate, Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, 323 Salk Pavilion, 335 Sutherland Drive, Pittsburgh, PA 15261, United States. pex9@pitt.edu |
| Key Words |
Fasudil; Liver fibrosis; Natural killer cell; Hepatic stellate cell; Clinical therapeutic drug |
| Core Tip |
This letter to the editor is to supplement the ongoing discussion on the therapeutic potentials of Fasudil in the treatment of hepatic fibrosis. Fasudil is potential for the treatment of liver fibrosis through activating natural killer cells and inhibiting the proliferation of hepatic stellate cells. Fasudil, a vasodilator used in clinical treatment of cerebral vasospasm, exhibits the protective and therapeutic effect on liver fibrosis. |
| Publish Date |
2021-12-03 07:34 |
| Citation |
Xi Y, Xu PF. Therapeutic potentials of fasudil in liver fibrosis. World J Gastroenterol 2021; 27(45): 7859-7861 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i45/7859.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i45.7859 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
